Welcome to CSNpharm! For Research Use Only!
Home +1-708-781-1677 sales@csnpharm.com    

BTK

BTK

Cat. No. Product Name CAS No. Information
CSN22147 Zanubrutinib 1691249-45-2 Zanubrutinib is a selective Bruton tyrosine kinase BTK inhibitor
CSN22532 Vecabrutinib 1510829-06-7 Vecabrutinib is a potent BTK inhibitor with IC50s of 46 nM and 11 nM for WT BTK and C481S BTK respectively and also inhibits ITK activity IC50 24 nM
CSN15892 RN486 1242156-23-5 RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM.
CSN13816 QL47 1469988-75-7 QL47 is a potent selective and irreversible BTK kinase inhibitor with IC50 of 7 nM
CSN20296 Poseltinib 1353552-97-2 Poseltinib irreversibly bound to and inhibited Btk IC50 value of 1.95nM. It inhibited the phosphorylation of Btk and its downstream molecules such as PLCγ2, in activated Ramos B lymphoma cells and primary human B cells in a dose-dependent manner.
CSN20637 PLS-123 1431727-04-6 PLS-123 is a covalent irreversible Btk inhibitor with potential anti-proliferative activity
CSN24174 PF-06250112 1609465-89-5 PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5nM, 0.9nM and 1.2nM for BTK, BMX Kinase and TEC, respectively.
CSN18605 PCI-32765 Racemate 936563-87-0 PCI-32765 racemate is a potent and highly selective Btk inhibitor with IC50 of 05 nM modestly potent to Bmx CSK FGR BRK HCK less potent to EGFR Yes ErbB2 JAK3 etc
CSN18219 PCI-29732 330786-25-9 PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
CSN17862 ONO-4059 HCl 1439901-97-9 ONO-4059 is a selective inhibitor of BTK with IC50 22 nm ONO-4059 binds to BTK within B cells thereby preventing B-cell receptor signaling and impeding B-cell development
CSN17733 ONO-4059 1351636-18-4 ONO-4059 is a highly selective and orally bioavailable BTK inhibitor with a IC50 of 2.2 nM.
CSN17732 ONO-4059 Analog 1351635-67-0 ONO-4059 Analog is a highly selective BTK inhibitor with IC50 of 22 nM
CSN22302 MT-802 2231744-29-7 MT-802 (MT802) is a potent BTK PROTAC that induces degradation of both wild-type and C481S mutant BTK (DC50=9.1 nM); MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome; MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency (>99% degradation at nanomolar concentrations) against wild-type and C481S BTK, elicits complete BTK knockdown at 250 nM; reduces the pool of active, phosphorylated BTK in cells isolated from CLL patients with the C481S mutation, whereas ibrutinib cannot.
CSN21709 LFM-A13 (mixture) 62004-35-7 LFM-A13 is specific inhibitor of bruton’s tyrosine kinase (BTK) with IC50 of 17.2 µM and 2.5 µM for recombinant BTK.
CSN19154 Ibrutinib-biotin 1599432-18-4 Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker with an IC50 of 0755-102 nM for BTK
CSN13636 Ibrutinib   936563-96-1 Ibrutinib is a potent Btk inhibitor with IC50 value of 0.5nM, modestly potent to Blk (IC50=0.5nM), Bmx (IC50=0.8nM), CSK (IC50=2.3nM), FGR (IC50=2.3nM), BRK (IC50=3.3nM), HCK (IC50=3.7nM).
CSN19159 GDC-0853 1434048-34-6 GDC-0853 is a potent and orally BTK inhibitor
CSN13839 GDC-0834 S-Enantiomer 1133432-50-4 GDC-0834 S-enantiomer is the S-enantiomer of GDC-0834
CSN17489 GDC-0834 Racemate 1133432-46-8 GDC-0834 racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.
CSN17490 GDC-0834 1133432-49-1 GDC-0834 is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.
CSN20295 Evobrutinib 1415823-73-2 Evobrutinib is a highly selective inhibitor of the Brutons tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Preclinical research suggests it may be therapeutically useful in certain autoimmune diseases.
CSN17176 CNX-774 1202759-32-7 CNX-774 is a potent and selective of Btk with IC50 1 nM
CSN18870 CHMFL-BTK-01 2095280-64-9 CHMFL-BTK-01 is an irreversible BTK inhibitor targeting Cys481 residue while completely abolishing BMX JAK3 and EGFRs activity
CSN13815 CGI-1746   910232-84-7 CGI-1746 is a Brutons tyrosine kinase (Btk) inhibitor.
CSN22295 BTK PROTAC 9 N/A BTK PROTAC 9 is a potent PROTAC for BTK with DC50 of 59 nM in cultured Ramos cells requires simultaneous engagement of BTK and CRBN to effectively degrade BTK TEC a closely related protein to BTK that potently binds BTK PROTAC 9 is also degraded
CSN22294 BTK PROTAC 10 N/A BTK PROTAC 10 is a potent PROTAC for BTK with DC50 of 11 nM in cultured Ramos cells can successfully delivered to tissues and can specifically degrade BTK in vivo in a dose-dependent and tissue-biased manner by sc administration
CSN13705 Btk Inhibitor 1 R-Enantiomer   1022150-12-4 Btk inhibitor 1 R-enantiomer is a Btk kinase inhibitor
CSN17926 Btk Inhibitor 1 R-Enantiomer HCl 1553977-42-6 Btk inhibitor 1 R-enantiomer HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
CSN17811 Btk Inhibitor 1 1412418-47-3 Btk inhibitor 1 is a pyrazolo34-dpyrimidine derivative as a Btk kinase inhibitor
CSN19157 Btk inhibitor 1 HCl 1807619-60-8 Btk inhibitor 1 HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
CSN24501 SNS-062 1270014-40-8 BTK IN-1 is a potent BTK inhibitor, with an IC50 of <100 nM.
CSN24257 BMS-986195   1912445-55-6 BMS-986195 is a potent, covalent, irreversible BTK inhibitor with IC50 value of 0.1nM.
CSN20297 BMS-986142 1643368-58-4 BMS-986142 is a potent, selective, reversible BTK inhibitor. BMS-986142 shows BTK IC50 0.5nM and human WB IC50 90 nM.
CSN19767 BMS-935177 1231889-53-4 BMS-935177 is a potent BTK inhibitor with improved kinase selectivity and superior oral exposure in multiple species. should provide useful clinical efficacy in autoimmune diseases.
CSN20168 Zanubrutinib (Recemate) 1633350-06-7 BGB-3111 is a potent selective and orally available Brutons tyrosine kinase Btk inhibitor
CSN16215 AVL-292   1202757-89-8 AVL-292 is a covalent and highly selective inhibitor of Btk with IC50 of 0.5 nM, exhibiting 1400-fold selectivity over the other kinases assayed.
CSN17749 AVL-292 Benzenesulfonate 1360053-81-1 AVL-292 benzenesulfonate is a potent inhibitor of Btk kinase activity (IC50 0.5 nM, KinactKi7.69104 M-1s-1s) in biochemical assays.
CSN21093 ARQ 531 2095393-15-8 ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity.
CSN16252 Acalabrutinib   1420477-60-6 Acalabrutinib is a second-generation selective and irreversible inhibitor of BTK Brutons tyrosine kinase with an IC50 of 3 nM and EC50 of 8 nM in a human whole-blood CD69 B cell activation assay Acalabrutinib has improved pharmacologic features including favorable plasma exposure rapid oral absorption a short half-life and the absence of irreversible targeting to alternative kinases
CSN22895 (-)-Terreic Acid 121-40-4 (-)-Terreic Acid is a selective inhibitor of Bruton's tyrosine kinase (BTK).
<< PREV 1 2 NEXT >>